Jeffrey Perl


Associate Scientist, Li Ka Shing Knowledge Institute


Dr. Jeffrey Perl received his MD from the University of Toronto in 2003, where he also completed his post-graduate training in both Internal Medicine and Nephrology in 2008. In 2010, he completed his Masters of Science in Clinical Epidemiology from The Harvard School of Public Health.

Dr. Perl is currently a Staff Nephrologist at St Michael’s Hospital in Toronto and an Assistant Professor in the Department of Medicine at the University of Toronto. He currently chairs the International Society of Nephrology’s Young Nephrologists Committee. His primary research interests and clinical practice focuses on improving the survival and quality of life for patients on peritoneal dialysis. Dr. Perl is a primary investigator in The Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS).

Recent Publications

  1. Walsh, M, Merkel, PA, Peh, CA, Szpirt, WM, Puéchal, X, Fujimoto, S et al.. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N. Engl. J. Med. 2020;382 (7):622-631. doi: 10.1056/NEJMoa1803537. PubMed PMID:32053298 .
  2. Manera, KE, Johnson, DW, Craig, JC, Shen, JI, Gutman, T, Cho, Y et al.. Establishing a Core Outcome Set for Peritoneal Dialysis: Report of the SONG-PD (Standardized Outcomes in Nephrology-Peritoneal Dialysis) Consensus Workshop. Am. J. Kidney Dis. 2020; :. doi: 10.1053/j.ajkd.2019.09.017. PubMed PMID:31955922 .
  3. Perl, J, Fuller, DS, Bieber, BA, Boudville, N, Kanjanabuch, T, Ito, Y et al.. Peritoneal Dialysis-Related Infection Rates and Outcomes: Results From the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). Am. J. Kidney Dis. 2020; :. doi: 10.1053/j.ajkd.2019.09.016. PubMed PMID:31932094 .
  4. Young, A, Beriault, D, Jung, B, Nikonova, A, Abosh, D, Lee, S et al.. DAMPAned Methotrexate: A Case Report and Review of the Management of Acute Methotrexate Toxicity. Can J Kidney Health Dis. 2019;6 :2054358119895078. doi: 10.1177/2054358119895078. PubMed PMID:31903191 PubMed Central PMC6926974.
  5. Thomas, A, Silver, SA, Perl, J, Freeman, M, Slater, JJ, Nash, DM et al.. The Frequency of Routine Blood Sampling and Patient Outcomes Among Maintenance Hemodialysis Recipients. Am. J. Kidney Dis. 2019; :. doi: 10.1053/j.ajkd.2019.08.016. PubMed PMID:31732233 .
  6. Silverstein, WK, Teshima, C, Jolly, S, Perl, J. Don't Interrupt! A Case Report of Continuing Peritoneal Dialysis After Endoscopic Gastric Tumor Resection. Can J Kidney Health Dis. 2019;6 :2054358119887147. doi: 10.1177/2054358119887147. PubMed PMID:31723433 PubMed Central PMC6836299.
  7. Bello, AK, Levin, A, Lunney, M, Osman, MA, Ye, F, Ashuntantang, GE et al.. Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. BMJ. 2019;367 :l5873. doi: 10.1136/bmj.l5873. PubMed PMID:31672760 .
  8. Nadeau-Fredette, AC, Chan, CT, Bargman, JM, Copland, MA, Finkle, SN, Oliver, MJ et al.. Predictors of Care Gaps in Home Dialysis: The Home Dialysis Virtual Ward Study. Am. J. Nephrol. 2019;50 (5):392-400. doi: 10.1159/000503439. PubMed PMID:31600760 .
  9. Perlman, RL, Zhao, J, Fuller, DS, Bieber, B, Li, Y, Pisoni, RL et al.. International Anemia Prevalence and Management in Peritoneal Dialysis Patients. Perit Dial Int. ;39 (6):539-546. doi: 10.3747/pdi.2018.00249. PubMed PMID:31582465 .
  10. Al Sahlawi, M, Liew, A, Perl, J. Cefepime as Empirical Peritoneal Dialysis-Associated Peritonitis Treatment: Something to Dwell On?. Am. J. Kidney Dis. 2019;74 (5):579-582. doi: 10.1053/j.ajkd.2019.06.008. PubMed PMID:31515138 .
Search PubMed

Affiliations & Other Activities

  • Nephrologist, Division of Nephrology, St. Michael’s Hospital
  • Assistant Professor of Medicine, University of Toronto
  • Chair, International Society of Nephrology’s Young Nephrologists Committee